Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

NEWRON PHARMACEUTICALS SPA

(NWRN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/13/2019 06/14/2019 06/17/2019 06/18/2019 06/19/2019 Date
6.24(c) 6.49(c) 6.22(c) 6.01(c) 6.12(c) Last
13 946 19 598 6 136 13 560 29 779 Volume
+2.30% +4.01% -4.16% -3.38% +1.83% Change
More quotes
Financials (EUR)
Sales 2019 8,31 M
EBIT 2019 -21,8 M
Net income 2019 -20,2 M
Finance 2019 28,1 M
Yield 2019 -
Sales 2020 17,0 M
EBIT 2020 -19,9 M
Net income 2020 -18,8 M
Finance 2020 16,6 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 9,10x
EV / Sales2020 5,11x
Capitalization 104 M
More Financials
Company
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company... 
Sector
Biotechnology & Medical Research
Calendar
06/19 | 10:00amPresentation
More about the company
Surperformance© ratings of Newron Pharmaceuticals SpA
Trading Rating : Investor Rating :
More Ratings
Latest news on NEWRON PHARMACEUTICALS SPA
06/13NEWRON PHARMACEUTICALS : to Present at the JMP Securities Life Sciences Conferen..
BU
05/28Newron Pharmaceuticals provides update on regulatory status of evenamide for ..
TE
05/23NEWRON PHARMACEUTICALS : to Present at the Jefferies 2019 Healthcare Conference
BU
04/03NEWRON PHARMACEUTICALS : S.p.A. - Shareholders accepted all motions at the 2019 ..
AQ
04/02Shareholders accepted all motions at the 2019 AGM
TE
03/05Newron announces 2018 financial results and provides outlook for 2019
TE
03/01NEWRON PHARMACEUTICALS : Supports Global Rare Disease Day 2019
AQ
02/28NEWRON PHARMACEUTICALS : Supports Global Rare Disease Day® 2019
BU
02/20NEWRON PHARMACEUTICALS : to Present at the 8th Annual SVB Leerink Global Healthc..
BU
02/04NEWRON PHARMACEUTICALS : Completes Patient Enrollment in Pivotal STARS Study
AQ
More news
Analyst Recommendations on NEWRON PHARMACEUTICALS SPA
More recommendations
Sector news : Bio Therapeutic Drugs
02:24pPFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
09:05aGILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
06/18PFIZER : Expands Cancer-Treatment Lineup
DJ
06/17ARRAY BIOPHARMA : Pfizer makes $10.6 billion cancer bet in cash deal for Array B..
RE
More sector news : Bio Therapeutic Drugs
Chart NEWRON PHARMACEUTICALS SPA
Duration : Period :
Newron Pharmaceuticals SpA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEWRON PHARMACEUTICALS SPA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 25,5 €
Spread / Average Target 338%
EPS Revisions
Managers
NameTitle
Stefan Weber Chief Executive Officer, Director & IR Contact
Ulrich Köstlin Non-Executive Chairman
Roberto Galli Vice President-Finance
Ravi Anand Chief Medical Officer
Patrick J. Langlois Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS SPA7.13%123
GILEAD SCIENCES7.27%80 909
VERTEX PHARMACEUTICALS4.87%42 680
REGENERON PHARMACEUTICALS-16.74%32 744
GENMAB13.49%10 857
SAREPTA THERAPEUTICS INC21.25%8 523